Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses.
about
Increasing antipsychotic dose for non response in schizophreniaIncreasing antipsychotic dose versus switching antipsychotic for non response in schizophreniaHaloperidol dose for the acute phase of schizophreniaIntermittent drug techniques for schizophreniaLithium for schizophreniaSurvey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patternsAntipsychotic dosing: found in translationChronic antipsychotic treatment: protracted decreases in phospho-TrkA levels in the rat hippocampusErythropoietin prevents haloperidol treatment-induced neuronal apoptosis through regulation of BDNFPrinciples of practice from the European expert panel on the contemporary treatment of schizophrenia.Carbamazepine for schizophrenia and schizoaffective psychoses.Haloperidol dose for the acute phase of schizophrenia.Different effects of amitriptyline and imipramine on the pharmacokinetics and metabolism of perazine in rats.The effect of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics and metabolism of perazine in the rat.Use of electronic medical record data for quality improvement in schizophrenia treatment.A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation.Conventional versus novel antipsychotics: changing concepts and clinical implicationsManaging antipsychotic-induced acute and chronic akathisia.Therapeutic drug monitoring of psychotropic medications.The use of carbamazepine in the treatment of schizophrenic and schizoaffective psychoses: a review.Patient compliance with drug therapy in schizophrenia. Economic and clinical issues.Determining the optimal dose of haloperidol in first-episode psychosis.Neuroleptic drug utilization in out-patients--a prescription database study.Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden.Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia.Pharmacological treatment of ambulatory schizophrenic patients in BelgiumLevomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial.Past and present progress in the pharmacologic treatment of schizophrenia.Reducing the rates of prescribing high-dose antipsychotics and polypharmacy on psychiatric inpatient and intensive care units: results of a 6-year quality improvement programme.State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotics.Antipsychotic drugs rapidly induce dopamine neuron depolarization block in a developmental rat model of schizophrenia.Understanding antipsychotic "atypicality": a clinical and pharmacological moving targetTreatment of the special patient with schizophrenia.Neuroleptic-induced movement disorders: deconstructing extrapyramidal symptoms.Oral haloperidol or risperidone treatment in rats: temporal effects on nerve growth factor receptors, cholinergic neurons, and memory performance.The impact of European regulatory policies on psychotropic drug prescribing patterns.Protracted effects of chronic oral haloperidol and risperidone on nerve growth factor, cholinergic neurons, and spatial reference learning in ratsTherapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.Determination of oxidative stress and activities of antioxidant enzymes in guinea pigs treated with haloperidol.Clinical utility of drug measurement and pharmacokinetics: therapeutic drug monitoring in psychiatry.
P2860
Q24186768-8DEE596D-50C2-48B9-81A7-38BA48F1D9EDQ24186772-99BEF21D-DA2E-43BD-9587-4F33AB7C75E4Q24200200-7957DB0A-134E-45AB-9A87-E866B63EC264Q24201124-6ED42F0B-3ECC-43FD-9593-4EEC037F0442Q24247988-F2B045A4-C8BB-4E20-975D-A9B278BFD3F9Q24802626-B6EC208B-1D9D-4CB9-9982-C3DA5C7DEAD3Q26863343-D682D717-8143-4412-95E7-CDC45AB50556Q28577430-41092013-2694-4AA3-96B9-0A6A490FA262Q28580029-0B550CCE-BEA7-4D86-8A41-889735C8194DQ30363590-3421F6F1-06DE-4CCB-B886-FEB22012111AQ30838723-3EB92B79-3B2A-4D4E-9B51-731BA796550BQ30838771-64062277-BD04-4630-8C45-F2A05081BC00Q33181695-1AE1D3A1-83BD-4A27-8C13-2EBFACDD72A1Q33181987-C2AB848C-56DC-45F4-8CC0-CB035FC092F7Q33203597-FA541049-D7F6-40BF-A846-5B1137CCE81BQ33699874-E0194207-E4CC-4B97-9379-4AE817DC9625Q33787546-990D604C-8728-4A62-934A-7E33243853EFQ33824853-E8E03F95-7F74-4283-8B9F-7930B5D33D69Q33888577-5E56C1AD-D2FE-4BF4-BA78-2111CBA92D2CQ33920998-54A864A4-342F-458E-B44A-3824E12BC769Q34078005-CAE68405-A5B2-4054-B5F0-E7C902029913Q34107268-91854BC7-5EC2-4A5C-A281-C309231156F0Q34345801-3A9E620B-38FA-4EE1-9A20-5C3935D145B7Q34347657-E46FB70A-1C72-4CC7-B424-870849580C8DQ34560981-BE29ECB4-73E3-4255-B36F-23E3EE081444Q34691376-509B4EDC-2D03-4344-A86C-EBEFFC1C2A92Q34716524-24C899E0-B859-4DEE-A3D9-2FD6A3759E6CQ34726953-DB1F9003-14F6-4A8E-A3B4-50B93EF55EE8Q35044176-E55C542E-4EBA-425C-8BF6-BE19252AF571Q35073834-1B1BC266-0EC0-4F71-805E-E16ECF8C329FQ35197029-52230515-61C8-46EF-BBF3-1D2745599302Q35200831-88A6D99C-BAF5-4D9C-BB93-33C74869B919Q35236370-F88E39FD-64C4-43C2-A8BF-65327B163EA4Q35947404-B08111BF-CA27-4D60-BAF5-8543A5125FD8Q35994829-2375A695-7E96-48F6-84DC-A834571D7CB2Q36272515-3D3D27F9-2A19-4FE5-AD55-BE2E0CF3EEE6Q36383589-48C00C84-3CA4-441C-951F-75BBEB17C716Q36582619-C292241A-0AB1-42FD-B72F-EB18BA81196EQ36603481-1FB7932E-BD3C-45BC-8ED6-2A3C8DDB42B8Q37057313-391D75C5-C19E-4758-88C1-818699E550C5
P2860
Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
Significance of neuroleptic do ...... ogical treatment of psychoses.
@en
Significance of neuroleptic do ...... ogical treatment of psychoses.
@nl
type
label
Significance of neuroleptic do ...... ogical treatment of psychoses.
@en
Significance of neuroleptic do ...... ogical treatment of psychoses.
@nl
prefLabel
Significance of neuroleptic do ...... ogical treatment of psychoses.
@en
Significance of neuroleptic do ...... ogical treatment of psychoses.
@nl
P2093
P1433
P1476
Significance of neuroleptic do ...... ogical treatment of psychoses.
@en
P2093
Baldessarini RJ
Teicher MH
P356
10.1001/ARCHPSYC.1988.01800250095013
P407
P577
1988-01-01T00:00:00Z